Opicapone Reduces Homocysteine Levels in Patients with Parkinson’s Disease Treated with Levodopa Gel Infusion
Objective: Our study aims to assess the effect of an add-on treatment with catechol-O-methyl transferase (COMT) inhibitor, opicapone, on the plasmatic levels of homocysteine (HCY)…Changes in Parkinson’s Disease and Parkinsonian Syndromes A Comparative Retrospective Study in Kyrgyzstan
Objective: This study compares Parkinson's disease (PD) and parkinsonian syndromes (PS) in patients at a Kyrgyzstan university hospital. It analyzes data from 2016-2017 [1] and…Buspirone/zolmitriptan combination exerts synergistic reduction in dyskinesia without worsening Parkinson disease motor symptomatology
Objective: Levodopa-induced dyskinesias (LID) may be amenable to interventions with striatal serotonergic receptors. Preclinical evidence suggests that co-administration of serotonergic agonists with selective receptor properties…Once-Daily Suvecaltamide Pharmacokinetics, Safety, & Tolerability–Phase 1, Randomized, Double-Blind, Multiple Ascending Dose Study
Objective: Evaluate the pharmacokinetics (PK), safety, and tolerability of a once-daily (QD) suvecaltamide (JZP385) formulation and its major active metabolites (JZZ05000034=M01, JZZ05000035=M02) in a Phase…A comprehensive at-home and in-hospital work-up of patients with Parkinson’s disease receiving fosflevodopa/fosfcarbidopa continuous subcutaneous infusion
Objective: Continuous infusion of fosflevodopa/foscarbidopa is a promising treatment for patients with Parkinson’s disease (PD) and severe motor fluctuations unresponsive to conventional therapy. Patient selection…Essential3: An Innovative Multi-Study Phase 3 Program to Evaluate the Efficacy and Safety of Ulixacaltamide
Objective: An innovative, multi-study Phase 3 program to definitively assess safety and efficacy of ulixacaltamide in essential tremor (ET). Background: Phase 2 studies of ulixacaltamide,…A case of malignant Deep Brain Stimulation Withdrawal Syndrome treated with Opicapone
Objective: We present a case of a patient with Parkinson's disease who developed "malignant Deep Brain Stimulation (DBS) Withdrawal Syndrome" following the removal of the…Impact of IPX203 on Parkinson’s patients’ motor states upon awakening: analysis of patient diary data
Objective: To evaluate “On” upon awakening in Parkinson’s disease patients taking IPX203 in the RISE-PD phase 3 clinical trial. Background: IPX203 is a novel extended-release,…Suvecaltamide Metabolites Are CaV3 Modulators and Contribute to Pharmacological Effect
Objective: To determine the potency-concentration relationships and combined pharmacological effects for suvecaltamide and its 2 active metabolites (JZZ05000034=M01, JZZ05000035=M02; total active moiety [TAM]). Background: T-type…Multicentric Randomized Control Trial of Buspirone in Levodopa-Induced Dyskinesias
Objective: To investigate the efficacy of buspirone on levodopa induced dyskinesias (LID) in Parkinson disease (PD) patients Background: LID could be partially mediated by the…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 34
- Next Page »